The proceeds from the Series B are expected to be used to advance Homology's lead development candidate that is currently in preclinical IND-enabling studies for an inborn error of metabolism disease. The proceeds are also expected to support continued work to progress Homology's AMEnDR (AAV-Mediated Editing by Direct Homologous Recombination) technology into the clinic for rare genetic diseases with high unmet medical need.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

45 Wiggins Ave.
Bedford, MA 01730
USA

Phone

Undisclosed

Website

www.homologymedicines.com

Email Address

[email protected]

Overview

Homology is a genetic medicines company translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases.

Profile

Social Media

Homology Medicines Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Arthur Tzianabos

Chief Financial Officer

Brad Smith

Chief Operating Officer

Sam Rasty

Chief Scientific Officer

Albert Seymour

Chief Technical Officer

Timothy Kelly

Vice President

Theresa McNeely

Browse more venture capital transactions:

Prev: 8/1/2017: district0x Network venture capital transaction
Next: 8/2/2017: FluGen venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary